Flex Pharma Picks Interim Executive William McVicar for CEO

Flex Pharma’s (NASDAQ: [[ticker:FLKS]]) interim CEO, William McVicar, is now officially the company’s top executive. McVicar had been serving as interim CEO of Boston-based Flex since June. He first joined Flex in April as president of research and development. Before joining Flex, McVicar was chief scientific officer of Lexington, MA-based Inotek Pharmaceuticals (NASDAQ: [[ticker:ITEK]]). Last October, Inotek announced that McVicar planned to leave the company. Flex’s lead drug, FLX-787, is slated to start Phase 2 clinical trials as a potential treatment for severe muscle cramps associated with amyotrophic lateral sclerosis.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan